<DOC>
	<DOCNO>NCT00286182</DOCNO>
	<brief_summary>The purpose study determine treat anemia subcutaneous erythropoetin patient heart failure preserve ejection fraction ( HFPEF ) associate reverse ventricular remodeling , significant improvement exercise capacity , improve health status , compare placebo .</brief_summary>
	<brief_title>Anemia Heart Failure With Preserved Ejection Fraction ( HFPEF )</brief_title>
	<detailed_description>Heart failure frequently occur patient preserved ejection fraction ( HFPEF ) affect subject predominantly elderly woman several co-morbid condition . Despite diversity underlie clinical pathology co-morbid condition present patient , common pathophysiologic explanation generally apply explain clinical symptom . Our preliminary data show significant subgroup HFPEF increase ventricular volume expand plasma volume , consistent volume overload state . In set preserve EF end diastolic volume increase , stroke volume must increase , indicate high output state . Anemia may important , modifiable contributor observe high output volume overload well exercise intolerance elderly HFPEF patient , abnormal ventricular remodel impaired overall health status quality life . This protocol evaluate impact treat anemia subject HFPEF . The specific aim current study provide comprehensive mechanistically base assessment correct anemia subject HFPEF impact functional capacity , ventricular structure function overall health status . We propose perform randomize , prospective , double blind study 80 subject HFPEF test hypothesis administration subcutaneous erythropoietin associated reverse ventricular remodeling , significant improvement exercise capacity improve health status .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Heart failure preserve ejection fraction ( HFPEF ) EF &gt; =40 % 2 . Anemia define hemoglobin &lt; 12 g/dL 3 . Age &gt; = 55 year 4 . Patients must able understand sign inform consent document nature study fully explain , prior begin study procedure . 1 . Presence uncontrolled hypertension ( Systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 90 mm Hg ) 2 . Resting heart rate &gt; 120 bpm 3 . Baseline 6minute walk test &gt; 450 meter 4 . Valvular heart disease ( e.g . mild regurgitant stenotic mitral , aortic , tricuspid , pulmonic valve disease ) . 5 . Infiltrative cardiac disease hemochromatosis amyloidosis 6 . Hypertrophic cardiomyopathy 7 . Chronic pulmonary disease ( FEV 1 &lt; 60 % predict ) 8 . Renal failure ( GFR &lt; 15 ml/min ) 9 . Hemoglobin &lt; 8 g/dL 10 . BMI &gt; 40 11 . Exercise limited angina , claudication , orthopedic , neurological disease . 12 . Severe liver dysfunction define international normalized ratio &gt; 2.0 , cause anticoagulant . 13 . Current recent treatment ( within past 6 month ) erythropoietin 14 . Erythropoietin level &gt; 100 mU/ml 15 . Recent cardiac surgery ( &lt; 3 month ) 16 . Known iron deficiency anemia chronic GI blood loss , uterine bleeding , chronic bleed 17 . Planned surgery course study 18 . Significant alcohol use illicit drug use . 19 . Patients know hypercoagulable state . 20 . Active hematologic disease ( e.g . sickle cell anemia , thalassemia , chronic myelogenous leukemia ) malignancy 21 . Patients current seizure disorder activity 22 . Patients know pregnant 23 . History deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) within 12 month study entry . Prior superficial thrombophlebitis exclusion criterion . 24 . History cerebrovascular accident ( CVA ) within 6 month 25 . History transient ischemic attack ( TIA ) within 6 month 26 . History acute coronary syndrome ( ACS ) , arterial thrombosis within 6 month study entry . ACS include unstable angina , Q wave myocardial infarction ( QwMI ) , nonQ wave myocardial infarction ( NQMI ) . 27 . Allergy sensitivity human serum albumin 28 . Known hypersensitivity mammalian cellderived product</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Elderly</keyword>
	<keyword>Diastolic Dysfunction</keyword>
	<keyword>Anemia</keyword>
	<keyword>Ventricular End Diastolic Volume</keyword>
	<keyword>Aged</keyword>
</DOC>